No profile data available.
BioCryst Pharmaceuticals, Inc. (BCRX) is a healthcare company in the immunodeficiency treatment drugs industry, based in Durham, United States, with about 435 full-time employees.
It reported revenue of $874.84 million for fiscal year 2025, up 94.1% from fiscal year 2024, and net income of $263.86 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $218.25 million, up 33.6% from a year before. United States was its largest region in fiscal year 2025, with 91% of revenue. Its market capitalization was $2.18 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases.
BioCryst Pharmaceuticals reported $874.84 million in revenue for fiscal year 2025, up 94.1% from $450.71 million in fiscal year 2024. In Q2 2026 revenue was $218.25 million.
United States: 91% of revenue by region in fiscal year 2025, followed by Outside United States (9%).
$2.18 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (immunodeficiency treatment drugs) include Pharvaris N.v. (PHVS), Pharming Group N.v. (PHAR), X4 Pharmaceuticals, Inc. (XFOR), AIM ImmunoTech Inc. (AIM).